-
公开(公告)号：EP3183266B1
公开(公告)日：2019-05-29
申请号：EP15787045.2
申请日：2015-08-20
IPC分类号： C07K16/18 , C12N15/13 , A61K39/395
-
公开(公告)号：EP3466968A1
公开(公告)日：2019-04-10
申请号：EP18195448.8
申请日：2011-09-14
发明人： MEEMS, Henriët , MEIJER, Alexander Benjamin , MERTENS, Koenraad , OLSEN, Ole Hvilsted , LAMBERTH, Kasper , NOERBY, Peder Lisby , JOHNSEN, Laust Bruun , KJALKE, Marianne , STENNICKE, Henning Ralf , VOORBERG, Johannes Jacobus , VAN DEN BIGGELAAR, Maartje
IPC分类号： C07K14/755 , A61K38/00
摘要： The present invention relates to modified coagulation factors. In particular, the present invention relates to modied Factor VIII molecules having decreased cellular uptake.
-
3.发明公开
公开(公告)号：EP3257866A1
公开(公告)日：2017-12-20
申请号：EP16175154.0
申请日：2016-06-17
IPC分类号： C07K16/24
CPC分类号： C07K16/242 , A61K2039/505 , C07K2317/41 , C07K2317/72 , C07K2317/76
摘要： The invention relates to modified anti-TNF antibody having an affinity for the 158V polymorfism of FcγRIIIa of more than 7.7 * 10 6 KA (M -1 ) as determined using biosensor analysis.
摘要翻译： 本发明涉及如使用生物传感器分析所测定的，对FcγRIIIa的158V多形态具有超过7.7×10 6 KA（M-1）的亲和力的经修饰的抗TNF抗体。
-
4.发明授权METHODS FOR INCREASING THE THERAPEUTIC EFFICACY OF IMMUNOGLOBULIN G CLASS 3 (IGG3) ANTIBODIES 有权方法，提高免疫球蛋白G CLASS-3（IgG3）的抗体的治疗功效
-
5.发明授权
公开(公告)号：EP1730311B1
公开(公告)日：2010-09-15
申请号：EP05729402.7
申请日：2005-03-31
发明人： BEIBOER, Sigrid, Herma, Wilma , WIERINGA-JELSMA, Hendrika , DEN DUNNEN, Johannes, Theodorus , DE HAAS, Maschenka
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6827 , C12Q1/686
摘要： A method of genotyping blood cell antigens comprising subjecting DNA from an individual of a mammalian species to a multiplex Polymerase Chain Reaction (PCR) to amplify and detectably label a region of the locus of at least two different blood cell antigens which contains the site of nucleotide polymorphism of said blood cell antigen and using the thus amplified and labeled DNA fragments to determine the genotype for each of said blood cell antigens. The multiplex PCR comprises the use of at least one pair of blood cell antigen-specific chimeric primers for each blood cell antigen to be genotyped and at least one detectably labeled universal primer, preferably a pair of detectably labeled universal primers. The universal primer(s) have a unique sequence not occurring in the DNA of said mammalian species. Each chimeric primer pair comprises a left chimeric primer and a right chimeric primer, each of them comprising a blood cell antigen-specific part at the 3' end and a universal part at the 5' end. The base sequence of the universal part of the chimeric primers corresponds to the base sequence of said at least one universal primer. The blood cell antigen-specific parts of the chimeric primer pair enclose a region of the locus of the blood cell antigen which contains the site of nucleotide polymorphism of said blood cell antigen. A kit for genotyping blood cell antigens by this method. A set of blood cell antigen-specific chimeric primer pairs and a set of blood cell antigen allele-specific oligonucleotide probes.
-
6.发明公开DIAGNOSTIC METHODS INVOLVING DETERMINING GENE COPY NUMBERS AND SNPs IN THE Fc RII/Fc RIII GENE CLUSTER, AND PROBES FOR USE IN SUCH METHODS TO DETECT SUSCEPTIBILITY TO AND TREATMENT EFFICACY IN AUTOIMMUNE DISEASES 有权随着对发现是否易在AUTOIMUUNKRANKHEITEN按Fc RII RIII FC基因簇中这样的方法基因拷贝数和SNP和使用探针的测定及疗效DIAGNOSTICHE过程
公开(公告)号：EP1989323A2
公开(公告)日：2008-11-12
申请号：EP06835684.9
申请日：2006-12-22
发明人： ROOS, Dirk , KUIJPERS, Taco Willem
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q1/6851 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172
摘要： The invention relates to diagnostic methods to predict whether a subject is predisposed for acquiring a disease or to predict the therapy responsiveness of an individual patient. Provided is a method for determining whether a subject is predisposed for developing an autoimmune disease, comprising determining in a sample isolated from said subject the amount of intact genes, or gene products thereof, of the FcϜRII/FcϜRIII gene cluster, said gene cluster comprising the FCGR2C, FCGR3A, FCGR2A and FCGR3B genes encoding an activating FcϜR, and FCGR2B encoding an inhibitory FcϜ R; and correlating said amount to the amount observed in a healthy population. Also provided is a method to predict the responsiveness of a subject to therapy with intravenous immunoglobulin (IVIg) therapy or a monospecific biological, such as a humanized or human monoclonal antibody or a chimeric molecule, comprising the C-terminal Fc-tail of IgG.
-
7.发明公开Method to reduce false positive outcomes in prion assays 审中-公开在Prionenassays，Verfahren zum Reduzieren von falsch-positiven Ergebnissen
公开(公告)号：EP1382690A1
公开(公告)日：2004-01-21
申请号：EP02077909.6
申请日：2002-07-17
发明人： van Oers, Josephus W. A. M. , van der Vorst, Teun J. K. , Hack, Cornelis E. , van Engelenburg, Franciscus A. C.
CPC分类号： C12Q1/37 , G01N33/6896 , G01N2800/2828
摘要： This invention relates to the field of prion diseases. A method is provided to reduce false positive outcomes in a test by monitoring the activity of a proteolytic enzyme in a test sample comprising providing the test sample with a substrate and contacting the enzyme with said substrate to allow conversion of the substrate by the enzyme into a detectable product and detecting said product. Use of a method according to the invention can improve the reliability of prion tests.
摘要翻译： 本发明涉及朊病毒疾病领域。 提供了一种通过监测测试样品中的蛋白水解酶的活性来减少测试中的假阳性结果的方法，包括向测试样品提供底物并使酶与所述底物接触以允许通过酶将底物转化为 可检测的产品并检测所述产品。 使用根据本发明的方法可以提高朊病毒试验的可靠性。
-
公开(公告)号：EP0982397A1
公开(公告)日：2000-03-01
申请号：EP98202181.8
申请日：1998-06-29
CPC分类号： C12N9/6451 , A61K38/00 , C12Y304/21038
摘要： Novel inhibitors of the contact system were developed by a) the discovery that the sequence encompassing the amino acid residues 39 to 47 of the heavy chain region of human FXII contributes to the binding of FXII to activators such as negatively charged surfaces; and b) the demonstration that peptides mimicking this identified sequence inhibit the binding of FXII to activators and prevent contact system activation in human plasma. These novel contact system inhibitors may be applied to prevent activation of the contact system of blood by artificial surfaces, or used as anti-inflammatory drug for the prophylactic or therapeutic treatment of human or animal diseases.
摘要翻译： 开发了接触系统的新型抑制剂：a）发现包含人FXII重链区域的氨基酸残基39至47的序列有助于FXII与活化剂如带负电荷的表面的结合; 和b）证明模仿该鉴定的序列的肽抑制FXII与激活剂的结合并防止人血浆中的接触系统活化。 这些新颖的接触系统抑制剂可以用于防止人造表面对血液接触系统的活化，或用作抗炎药物用于预防或治疗人或动物疾病。
-
公开(公告)号：EP0920502A1
公开(公告)日：1999-06-09
申请号：EP97935896.0
申请日：1997-08-11
CPC分类号： C07K14/70596 , A61K38/00
摘要： CD97 is an activation-induced antigen on leucocytes with a seven-span transmembrane (7-TM) region homologous to the secretin receptor superfamily. However, in contrast to this group of peptide hormone receptors, CD97 has an extended extracellular region with three EGF domains at the N-terminus, two of them with a calcium binding site. Lymphocytes and erythrocytes specifically adhere to CD97-transfected COS cells which is blocked by a monoclonal antibody (mAb) directed to the N-terminal short consensus repeat (SCR) of decay accelerating factor (DAF, CD55), a regulatory protein of the complement cascade. Erythrocytes that lack CD55, obtained from patients with paroxysmal nocturnal hemoglobinuria (PNH) or the CD55- phenotype Inab, failed to adhere to CD97 transfectants. The invention provides methods and means to interfere in the binding of CD97 and CD55. This will be especially useful in xenotransplant medicine where CD55 is used to down regulate the complement activation pathway.
-
10.发明公开POTENTIATION OF COMPLEMENT AND COAGULATION INHIBITORY PROPERTIES OF C1-INHIBITOR. 失效KOMPLEMENT的增强和凝块-C1灭活剂性能的
公开(公告)号：EP0868191A1
公开(公告)日：1998-10-07
申请号：EP96941227.0
申请日：1996-12-18
CPC分类号： A61K31/737 , A61K38/55 , A61K31/715 , A61K2300/00
摘要： Dextran sulphate is used to potentiate C1-esterase inhibitor selectively with respect to inhibition of complement and coagulation, but not with respect to inhibition of the contact and fibrinolytic systems. The C1-esterase inhibitor to be potentiated by the dextran sulphate may be endogenous C1-esterase inhibitor, or exogenous C1-esterase inhibitor which is to be administered together with or separate from the dextran sulphate. Use of the dextran sulphate, alone or together with C1-esterase inhibitor, in prophylactic or therapeutic treatment of inflammatory conditions, such as sepsis and myocardial infarction.
-
-
-
-
-
-
-
-
-
搜索结果
64 条记录 (耗时 0.022 秒)
